Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis. The primary endpoint was modified Rodnan Skin Score at 12 months. Clinically meaningful improvements in mRSS and other outcome measures were observed in both the abatacept and placebo groups.
